<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01359696</url>
  </required_header>
  <id_info>
    <org_study_id>DPM4957g</org_study_id>
    <secondary_id>GO00767</secondary_id>
    <nct_id>NCT01359696</nct_id>
  </id_info>
  <brief_title>A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0425 Administered With and Without Gemcitabine in Patients With Refractory Solid Tumors or Lymphoma</brief_title>
  <official_title>An Open-Label, Phase I, Dose Escalation Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0425 Administered With and Without Gemcitabine in Patients With Refractory Solid Tumors or Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genentech, Inc.</source>
  <brief_summary>
    <textblock>
      This is an open-label, multicenter, Phase I, dose-escalation study to assess the safety,&#xD;
      tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of GDC-0425 administered with&#xD;
      and without gemcitabine.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 11, 2011</start_date>
  <completion_date type="Actual">May 29, 2014</completion_date>
  <primary_completion_date type="Actual">May 29, 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of all adverse events graded according to NCI CTCAE, v4.0</measure>
    <time_frame>Up to 1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of dose limiting toxicities (DLTs)</measure>
    <time_frame>Up to 35 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic property of GDC-0425: determination of plasma drug concentration</measure>
    <time_frame>Up to 12 months or early study discontinuation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic property of GDC-0425: exposure</measure>
    <time_frame>Up to 12 months or early study discontinuation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic property of GDC-0425: half-life</measure>
    <time_frame>Up to 12 months or early study discontinuation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Severity of all adverse events graded according to NCI CTCAE, v4.0</measure>
    <time_frame>Up to 1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Antitumor activity of GDC-0425 in combination with gemcitabine: determination of tumor response using RECIST v1.1 for patients with measurable disease</measure>
    <time_frame>Up to 12 months or early study discontinuation</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Solid Tumor</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GDC-0425</intervention_name>
    <description>Oral escalating dose</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine</intervention_name>
    <description>Intravenous repeating dose</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt;= 18 years&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 1&#xD;
&#xD;
          -  Signed Informed Consent Form&#xD;
&#xD;
          -  Histologically or cytologically documented, locally advanced or metastatic solid&#xD;
             tumors or lymphoma for which standard therapy either does not exist or has proven&#xD;
             ineffective or intolerable&#xD;
&#xD;
          -  Adequate hematologic and end-organ (liver and kidney) function&#xD;
&#xD;
          -  For female patients of childbearing potential and male patients with partners of&#xD;
             childbearing potential, agreement by the patient that the patient and/or partner will&#xD;
             use an effective form of contraception&#xD;
&#xD;
          -  Patients enrolled in certain phases must be willing to provide fresh and/or archival&#xD;
             tumor samples&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of prior significant toxicity from a same class of agents as GDC-0425 or&#xD;
             gemcitabine requiring discontinuation of treatment&#xD;
&#xD;
          -  Allergy, hypersensitivity or contraindication to the GDC-0425 formulation or&#xD;
             gemcitabine&#xD;
&#xD;
          -  Experimental therapy or anti-cancer therapy within 4 weeks prior to the first dose of&#xD;
             study drug treatment&#xD;
&#xD;
          -  Radiotherapy within 2 weeks prior to first dose of study drug treatment&#xD;
&#xD;
          -  More than two regimens of cytotoxic chemotherapy for the treatment of locally advanced&#xD;
             or metastatic cancer&#xD;
&#xD;
          -  History of receiving high-dose chemotherapy requiring bone marrow or stem cell support&#xD;
&#xD;
          -  History of receiving radiation to more than 25% of bone marrow-bearing areas&#xD;
&#xD;
          -  Acute drug-related toxicities from previous therapies have not resolved prior to study&#xD;
             entry, except for alopecia and mild neuropathy&#xD;
&#xD;
          -  Current severe, uncontrolled systemic disease (including but not limited to clinically&#xD;
             significant cardiovascular, pulmonary, or renal disease or ongoing or active&#xD;
             infection) excluding cancer&#xD;
&#xD;
          -  Significant heart disease and heart dysfunction including but not limited to&#xD;
             uncontrolled severe hypertension, heart failure, and reduced cardiac contractility&#xD;
&#xD;
          -  Uncontrolled ascites, due to diseases other than cancer&#xD;
&#xD;
          -  Inability or unwillingness to swallow pills/capsules&#xD;
&#xD;
          -  History of malabsorption or other condition that would interfere with drug absorption&#xD;
&#xD;
          -  Any history of active stomach and/or intestine bleeding within the 6 months prior to&#xD;
             screening&#xD;
&#xD;
          -  Known HIV infection&#xD;
&#xD;
          -  Pregnancy, lactation, or breastfeeding&#xD;
&#xD;
          -  Known brain metastases that are untreated, symptomatic, or require therapy to control&#xD;
             symptoms&#xD;
&#xD;
          -  Inability to comply with study and follow up procedures&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chia Portera, M.D., Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Genentech, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Karmanos Cancer Institute..</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy; Ser. de Med. Nucleaire; Cancerologie Endo</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <study_first_submitted>May 23, 2011</study_first_submitted>
  <study_first_submitted_qc>May 24, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 25, 2011</study_first_posted>
  <last_update_submitted>April 11, 2017</last_update_submitted>
  <last_update_submitted_qc>April 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>solid cancers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

